In a patient with a large 22q11.2 deletion encompassing the FGFR3 gene, how does the clinical phenotype and management differ between FGFR3 deletion (haploinsufficiency) and a gain‑of‑function FGFR3 mutation?

FGFR3 Deletion vs. Gain-of-Function Mutation: Fundamentally Opposite Clinical Phenotypes

FGFR3 deletion (haploinsufficiency) in 22q11.2 deletion syndrome produces no skeletal phenotype, while FGFR3 gain-of-function mutations cause achondroplasia—the most common genetic form of dwarfism.

Core Pathophysiologic Distinction

FGFR3 Deletion (22q11.2DS Context)

• FGFR3 is located within the 22q11.2 region (LCR22A-LCR22D) but is NOT a primary driver of 22q11.2DS phenotype 1
• The deletion encompasses multiple genes; TBX1 is the critical gene responsible for most 22q11.2DS features 2, 3
• FGFR3 haploinsufficiency produces no recognizable skeletal dysplasia or growth abnormalities attributable to FGFR3 loss alone
• Loss of one FGFR3 copy is clinically silent regarding bone development

FGFR3 Gain-of-Function Mutations

• G380R mutation (glycine→arginine at position 380 in transmembrane domain) causes achondroplasia in >98% of cases 4
• This represents a constitutive activation of FGFR3 signaling
• Results in inhibition of endochondral ossification, causing:
  • Rhizomelic limb shortening (proximal > distal)
  • Macrocephaly with frontal bossing
  • Midface hypoplasia
  • Adult height typically 118-145 cm

Clinical Phenotype Comparison

22q11.2 Deletion Syndrome (with FGFR3 deletion)

The clinical presentation reflects haploinsufficiency of multiple genes, not FGFR3 specifically 1, 3:

Cardiac (86.2%):

• Conotruncal defects (tetralogy of Fallot, truncus arteriosus)
• Requires lifelong cardiology follow-up 5

Immunologic (93.1% with lymphopenia):

• T-cell lymphopenia (71.9%) from thymic hypoplasia
• CD4+ lymphopenia (64.1%)
• Complete DiGeorge in 2.3% requiring HSCT 5, 6

Endocrine:

• Hypocalcemia from parathyroid hypoplasia (monitor calcium, PTH, magnesium, TSH, creatinine regularly) 7
• Hypothyroidism (25% require treatment, onset decades earlier than general population) 7
• Type 2 diabetes (18 years younger onset than expected) 7

Craniofacial:

• Velopharyngeal insufficiency
• Palatal defects
• No achondroplasia-type skeletal dysplasia

Neuropsychiatric:

• Developmental delay/intellectual disability
• Schizophrenia risk (25-30% by adulthood)
• Anxiety, depression 8, 3

Achondroplasia (FGFR3 Gain-of-Function)

Skeletal-dominant phenotype 4:

• Disproportionate short stature (rhizomelic)
• Macrocephaly with normal intelligence
• Lumbar lordosis, genu varum
• Foramen magnum stenosis (risk of cervicomedullary compression)
• Spinal stenosis
• No cardiac, immunologic, or endocrine features of 22q11.2DS

Management Differences

22q11.2 Deletion Syndrome Management

Requires multidisciplinary surveillance 7, 1:

Immunology:

• Baseline: Complete blood count with differential, lymphocyte subsets, immunoglobulins, vaccine titers
• Monitor T-cell recovery (may improve by age 3 years) 5, 6
• Live vaccines contraindicated if CD4+ <500/μL or <15% of total lymphocytes
• Prophylactic antibiotics if severe T-cell deficiency
• HSCT for complete DiGeorge syndrome

Endocrine:

• Annual TSH screening
• Regular calcium, PTH, magnesium, vitamin D monitoring
• Perioperative calcium monitoring (vulnerable period) 7
• Daily vitamin D supplementation for all adults
• Calcitriol reserved for severe/refractory hypocalcemia with endocrinology consultation

Cardiology:

• Lifelong adult CHD center follow-up
• Periodic aortic root assessment even without CHD history 7

Psychiatry:

• Early intervention for developmental delays
• Psychiatric surveillance intensifying in adolescence
• Avoid marijuana (increases psychosis risk) 1

Transition Planning:

• Neuropsychological assessment before age 18
• Guardianship consideration
• Transfer passport for adult providers 8

Achondroplasia Management

Orthopedic/skeletal focus:

• Foramen magnum decompression if symptomatic stenosis
• Limb lengthening procedures (controversial)
• Spinal stenosis monitoring
• Growth hormone therapy (limited efficacy)
• Vosoritide (FGFR3 antagonist) recently approved for children ≥5 years

Critical Clinical Pitfall

Do not attribute 22q11.2DS features to FGFR3 deletion. The 22q11.2 deletion encompasses 40-60 genes depending on deletion size 1. FGFR3 haploinsufficiency is phenotypically silent in the context of skeletal development. The complex 22q11.2DS phenotype results from:

• TBX1 haploinsufficiency (primary driver of cardiac, thymic, parathyroid defects) 2, 3
• DGCR8 (neurocognitive features)
• Other genes including COMT, PRODH, SNAP29 1, 9

Conversely, achondroplasia patients do not have 22q11.2DS features unless they coincidentally have both conditions (extraordinarily rare).

Genetic Counseling Distinctions

22q11.2 Deletion:

• 90% de novo, 10% inherited
• 50% recurrence if parent affected
• Phenotypic variability even within families 9, 3

Achondroplasia:

• 80% de novo (advanced paternal age association)
• 50% recurrence if parent affected
• Homozygosity is lethal 4